Search - tctmd.com

Displaying 421 - 440 of 1726

Sort: Relevancy | Date

Presentation TCT 2019

There Are No Circumstances in Which I Have to Use DCB/DES

Presenter: Konstantinos Katsanos

September 26, 2019

Presentation TCT 2019

Virtue® SEB: Promising Data for Innovative LIMUS Delivery

Presenter: Juan Granada

September 26, 2019

Presentation TCT 2019

Potential Hazards of Re-Stenting

Presenter: David Kandzari

September 26, 2019

Presentation TCT 2019

Current DCBs: Challenges of Paclitaxel and the Downsides of Coatings

Presenter: Robert Byrne

September 26, 2019

Presentation TCT 2019

TCT 64: Intravascular Molecular-Structural Imaging of Arterial Permeability and Vascular Injury In Vivo: Implications for Drug-Coated Balloon Efficacy

Presenter: Mazen Albaghdadi

September 25, 2019

Presentation TCT 2019

TCT 56: Impact of Neoatherosclerosis on clinical Outcomes after Repeat Revascularization of In-Stent Restenosis of 2nd Generation Drug-Eluting Stents

Presenter: Zhaoyang Chen

September 25, 2019

Presentation TCT 2019

TCT 48: Bioresorbable Scaffold Versus Metallic Drug-Eluting Stent in Patients at High Risk of Restenosis (COMPARE-ABSORB trial) : Very late device thrombosis while on extended DAPT

Presenter: Robert-Jan Van Geuns

September 25, 2019

Presentation TCT 2019

TCT 47: Five-Year Clinical Outcomes From Randomized Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents in Patients With Coronary Artery Disease From ABSORB China Trial

Presenter: Run-Lin Gao

September 25, 2019

Presentation TCT 2019

DCBs for Infrainguinal Arterial Occlusive Disease With or Without Adjunctive Techniques Are Better Than Primary Stenting

Presenter: Brian DeRubertis

September 25, 2019

Presentation TCT 2019

TCT 46: FANTOM II trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report on Initial 48 Month Outcomes

Presenter: Alexandre Abizaid

September 25, 2019

Presentation TCT 2019

TCT 45: Safety and Performance of the Resorbable Magnesium Scaffold, Magmaris in a Real World Setting - First Cohort Subjects at 12-month Follow-up of the BIOSOLVE-IV Registry

Presenter: Stefan Verheye

September 25, 2019

Presentation TCT 2019

TCT 44: Impact of Stent Edge Hinging on Chronic Neointimal Hyperplasia after Newer Generation Drug-Eluting Stent Placement in RCA

Presenter: Takahiro Jimba

September 25, 2019

Presentation TCT 2019

TCT 43: A Prospective Randomized Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus Eluting Stent in the Treatment of Subjects with up to two de novo Coronary Artery Lesions – BIOFLOW IV: 4 Years Clinical Results

Presenter: Bernhard Witzenbichler

September 25, 2019

Presentation TCT 2019

TCT 11: Everolimus-eluting Bioresorbable Scaffolds versus Drug-eluting Stents in Patients with Acute Myocardial Infarction – 2-Year Results of the Randomized ISAR-Absorb MI Trial

Presenter: Jens Wiebe

September 25, 2019

Presentation TCT 2019

TCT 42: Polymer-free Drug-coated vs. Bare-metal Coronary Stents in Patients Undergoing Non-cardiac Surgery A Subgroup Analysis of the LEADERS FREE Trial

Presenter: Abdelhakim Allali

September 25, 2019

Presentation TCT 2019

Industry Perspective on Drug-Eluting Technologies Guidance

Presenter: Mark Pacyna

September 25, 2019

Presentation TCT 2019

TCT 41: A prospective multicentre randomized all-comers trial to assess the safety and effectiveness of the ultra-thin-strut sirolimus-eluting coronary stent Supraflex: 2-year results of the TALENT trial

Presenter: Azfar Zaman

September 25, 2019

Presentation TCT 2019

FDA Perspective and Revised Guidance

Presenter: Eleni Whatley

September 25, 2019

Presentation TCT 2019

New Data Regarding Drug-Eluting Technologies

Presenter: Krishna Rocha-Singh

September 25, 2019

Presentation TCT 2019

An Unforeseen Setback: Summary Level Meta-Analysis Brings Practice Back to the 1990s.

Presenter: Michael Jaff

September 25, 2019

Advertisement

There Are No Circumstances in Which I Have to Use DCB/DES

Virtue® SEB: Promising Data for Innovative LIMUS Delivery

Potential Hazards of Re-Stenting

Current DCBs: Challenges of Paclitaxel and the Downsides of Coatings

TCT 64: Intravascular Molecular-Structural Imaging of Arterial Permeability and Vascular Injury In Vivo: Implications for Drug-Coated Balloon Efficacy

TCT 56: Impact of Neoatherosclerosis on clinical Outcomes after Repeat Revascularization of In-Stent Restenosis of 2nd Generation Drug-Eluting Stents

TCT 48: Bioresorbable Scaffold Versus Metallic Drug-Eluting Stent in Patients at High Risk of Restenosis (COMPARE-ABSORB trial) : Very late device thrombosis while on extended DAPT

TCT 47: Five-Year Clinical Outcomes From Randomized Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents in Patients With Coronary Artery Disease From ABSORB China Trial

DCBs for Infrainguinal Arterial Occlusive Disease With or Without Adjunctive Techniques Are Better Than Primary Stenting

TCT 46: FANTOM II trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report on Initial 48 Month Outcomes

TCT 45: Safety and Performance of the Resorbable Magnesium Scaffold, Magmaris in a Real World Setting - First Cohort Subjects at 12-month Follow-up of the BIOSOLVE-IV Registry

TCT 44: Impact of Stent Edge Hinging on Chronic Neointimal Hyperplasia after Newer Generation Drug-Eluting Stent Placement in RCA

TCT 43: A Prospective Randomized Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus Eluting Stent in the Treatment of Subjects with up to two de novo Coronary Artery Lesions – BIOFLOW IV: 4 Years Clinical Results

TCT 11: Everolimus-eluting Bioresorbable Scaffolds versus Drug-eluting Stents in Patients with Acute Myocardial Infarction – 2-Year Results of the Randomized ISAR-Absorb MI Trial

TCT 42: Polymer-free Drug-coated vs. Bare-metal Coronary Stents in Patients Undergoing Non-cardiac Surgery A Subgroup Analysis of the LEADERS FREE Trial

Industry Perspective on Drug-Eluting Technologies Guidance

TCT 41: A prospective multicentre randomized all-comers trial to assess the safety and effectiveness of the ultra-thin-strut sirolimus-eluting coronary stent Supraflex: 2-year results of the TALENT trial

FDA Perspective and Revised Guidance

New Data Regarding Drug-Eluting Technologies

An Unforeseen Setback: Summary Level Meta-Analysis Brings Practice Back to the 1990s.

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content